AKBA : Insider Transactions for Akebia Therapeutics, Inc. | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Akebia Therapeutics, Inc. (AKBA)

$1.14

0.04 (3.39%) as of 4:30 Thu 5/16

Download

Exchange:

N/A

Security Type:

N/A

Shares Out:

144,540,000

Market Cap:

164.78(M)

Last Volume:

0

Avg Vol:

0

52 Week Range:

$0.8 - $2.24

Level I Sector:

N/A

Level II Sector:

N/A

Level III Sector:

N/A

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : -

Guru Rank Value : -

Guru Occurances : -


6 Months 1 Year 2 Year

Company Profile Akebia Therapeutics is a biopharmaceutical company. Co.'s portfolio includes a late-stage product candidate and a commercial product: Vadadustat, which is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability; and Auryxia® (ferric citrate), which is approved and marketed in the U.S. for two indications which are the control of serum phosphorus levels in adult patients with chronic kidney disease (CKD) on dialysis or the Hyperphosphatemia Indication, and the treatment of iron deficiency anemia (IDA) in adult patients with CKD not on dialysis or the IDA Indication.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	0
Total Buy Value	$0	$0	$0	$0
Total People Bought	0	0	0	0
Total Buy Transactions	0	0	0	0
Total Shares Sold	132,629	203,429	516,227	739,065
Total Sell Value	$205,699	$324,643	$685,503	$873,568
Total People Sold	4	4	5	6
Total Sell Transactions	8	10	15	27
End Date	2024-02-15	2023-11-14	2023-05-16	2022-05-16

Adjust Filter Settings

Records found: 247

Page 8 of 10

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

Hadas Nicole R.

SVP, General Counsel, Sec.

• – –

2017-10-02

4

AS

$19.64

$155,188

D/D

(7,803)

101,804

-

SVP, Chief Business Officer

• – –

2017-10-02

4

AS

$19.64

$27,457

D/D

(1,398)

95,826

-

– • –

2017-10-02

4

AS

$19.64

$23,332

D/D

(1,188)

22,499

-

SVP, Chief Business Officer

• – –

2017-09-28

4

AS

$19.30

$96,500

D/D

(5,000)

97,224

-

SVP, Chief Business Officer

• – –

2017-08-15

4

AS

$15.00

$75,000

D/D

(5,000)

102,224

-

Satter Muneer A

Director

– • –

2017-07-05

4

B

$14.50

$14,999,989

I/I

1,034,482

3,037,042

2.1

-

SVP, Chief Business Officer

• – –

2017-07-03

4

S

$14.26

$19,947

D/D

(1,399)

107,224

-

Hadas Nicole R.

SVP, General Counsel, Sec.

• – –

2017-07-03

4

S

$14.26

$22,156

D/D

(1,554)

109,607

-

– • –

2017-07-03

4

AS

$14.27

$14,127

D/D

(990)

23,687

-

– • –

2017-04-03

4

AS

$9.20

$9,119

D/D

(991)

24,677

-

SVP, Chief Business Officer

• – –

2017-04-03

4

S

$9.18

$12,858

D/D

(1,401)

108,623

-

Hadas Nicole R.

SVP, General Counsel, Sec.

• – –

2017-04-03

4

S

$9.18

$14,280

D/D

(1,556)

109,856

-

SVP, CFO & Treasurer

• – –

2017-02-21

4

A

$0.00

$0

D/D

30,000

65,637

-

Tubridy Karen L

SVP, Chief Development Officer

• – –

2017-02-21

4

A

$0.00

$0

D/D

23,000

23,000

-

SVP and Chief Medical Officer

• – –

2017-02-21

4

A

$0.00

$0

D/D

23,500

64,585

-

Hadas Nicole R.

SVP, General Counsel, Sec.

• – –

2017-02-21

4

A

$0.00

$0

D/D

28,500

111,412

-

– • –

2017-01-03

4

AS

$10.46

$20,711

D/D

(1,980)

25,668

-

SVP, Chief Business Officer

• – –

2017-01-01

4

S

$10.49

$17,089

D/D

(1,629)

70,524

-

Hadas Nicole R.

SVP, General Counsel, Sec.

• – –

2017-01-01

4

S

$10.49

$18,988

D/D

(1,810)

82,912

-

– • –

2016-10-03

4

AS

$8.96

$17,746

D/D

(1,981)

27,648

-

SVP, Chief Business Officer

• – –

2016-10-01

4

S

$8.95

$12,546

D/D

(1,401)

72,153

-

Hadas Nicole R.

SVP, General Counsel, Sec.

• – –

2016-10-01

4

S

$8.95

$13,934

D/D

(1,556)

83,915

-

– • –

2016-07-06

4

AS

$7.48

$14,819

D/D

(1,980)

29,629

-

Hadas Nicole R.

SVP, General Counsel, Sec.

• – –

2016-07-05

4

S

$7.47

$11,625

D/D

(1,557)

85,471

-

SVP, Chief Business Officer

• – –

2016-07-05

4

S

$7.47

$10,468

D/D

(1,402)

73,554

-

247 Records found	1 2 3 4 5 6 7 8 9 Next	Page 8 of 10

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.